EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials

Hanke Zheng, Julie A Patterson, Jonathan D Campbell

Therapeutic Innovation & Regulatory Science · 2025

DOI: 10.1007/s43441-025-00774-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Hanke Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Pharmaceutical Council, Washington, DC, USA. Hauptthemen laut MEDLINE: Drug Development, Drug Industry, Clinical Trials as Topic, Drug Costs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Inflation Reduction Act’s (IRA) Drug Price Negotiation Program (DPNP) may reduce incentives for industry investments in post-approval clinical development. We aimed to explore the IRA’s impact on the initiation of industry-sponsored, post-approval clinical trials.

Methods

Using Citeline’s Trialtrove database (7/2014–8/2024), we conducted an interrupted time series analysis (ITSA) to estimate the IRA’s impact on the initiation of industry-sponsored Phase I-III trials in previously approved drugs, excluding all vaccines and COVID-19 treatments. We conducted an additional ITSA to examine post-IRA changes in government-funded trials, hypothesized to be unaffected by the IRA, and sensitivity analyses to explore potential exogenous confounding factors. Finally, we explored differences in the IRA’s impact on post-approval industry-sponsored clinical trial initiation in small versus large molecule drugs.

Results

Following the IRA’s passage, the average monthly number of industry-sponsored trials on post-approval drugs decreased by 38.4%. The ITSA indicated that the IRA’s passage was associated with an immediate drop of 11.1 industry-sponsored trials (p-value < 0.05) and an additional decrease by 0.9 trials per month (p-value < 0.01). The IRA’s passage was not statistically associated with changes in government-funded trial initiation. Sensitivity analyses supported ITSA findings. Initiation of post-approval industry-sponsored trials decreased by 47.3% and 32.9% for small and large molecule drugs, respectively.

Conclusions

The IRA’s passage was associated with reductions in industry-sponsored, but not government-funded, post-approval trials, with larger reductions for small molecule drugs. These findings provide early evidence supporting concerns around IRA-related reductions in incentives for post-approval clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentDrug IndustryClinical Trials as TopicDrug CostsDrug ApprovalHumansInterrupted Time Series AnalysisUnited States

Stichwörter der Autor:innen

Drug price negotiation programHealth policyHealthcare innovationInflation reduction actPost-approval clinical development

Autor:innen und Institutionen

  • National Pharmaceutical Council, Washington, DC, USA.
  • National Pharmaceutical Council, Washington, DC, USA. jcampbell@npcnow.org.

Zitieren

APA

Zheng, H., Patterson, J. A., & Campbell, J. D. (2025). The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00774-2

Vancouver

Zheng H, Patterson JA, Campbell JD. The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00774-2

BibTeX
@article{Zheng2025,
  author = {Zheng, Hanke and Patterson, Julie A and Campbell, Jonathan D},
  title = {The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  doi = {10.1007/s43441-025-00774-2}
}
Kostenlos starten →